Shares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company’s announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.
Gotham Green Partners, a backer of MedMen, is the seller on the deal.
Tilray’s stock TLRY,
Don’t miss: Tilray eyes U.S. cannabis market with MedMen deal, stock gains.
Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen’s current footprint includes dispensaries in New York and California.
“While an equity interest in a larger multi-state operator (MSO) would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,” Grey wrote in a research note.
He maintained his neutral rating on Tilray.
Also read: Tilray and Aphria merger closes and creates world’s biggest week company by revenue.
Meanwhile, Oppenheimer & Co.’s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a “meaningful” contribution from the U.S. market.
“We continue to look favorably upon management’s efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,” Parikh said.”
Tilray’s stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the Cannabis ETF THCX,
